Journal
BIOLOGICAL PSYCHIATRY
Volume 73, Issue 7, Pages 679-682Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.biopsych.2012.10.030
Keywords
Antidepressant; GCTA; genetics; GWAS; heritability; pharmacogenomics
Categories
Funding
- Innovative Medicine Initiative [115008]
- European Union
- European Commission [LSHB-CT-2003-503428]
- GlaxoSmithKline [G0701420]
- UK National Institute for Health Research of the Department of Health
- U.K. Medical Research Council [G0701420]
- Mental Health Research Network
- Swiss branch of GlaxoSmithKline
- Swiss branch of Wyeth-Lederle
- Swiss branch of Bristol-Myers-Squibb
- Swiss branch of Sanofi Aventis
- NIMH [N01MH90003, MH072802]
- Medical Research Council [G0701420, G0200243, G9817803B] Funding Source: researchfish
- MRC [G0701420, G0200243] Funding Source: UKRI
Ask authors/readers for more resources
Background: Pharmacogenetic studies aiming to personalize the treatment of depression are based on the assumption that response to antidepressants is a heritable trait, but there is no compelling evidence to support this. Methods: We estimate the contribution of common genetic variation to antidepressant response with Genome-Wide Complex Trait Analysis in a combined sample of 2799 antidepressant-treated subjects with major depressive disorder and genome-wide genotype data. Results: We find that common genetic variants explain 42% (SE = .180, p = .009) of individual differences in antidepressant response. Conclusions: These results suggest that response to antidepressants is a complex trait with substantial contribution from a large number of common genetic variants of small effect.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available